Pancreatic cancer treatment pipeline dominated by early-stage development

Almost 75 percent of pipeline therapies for pancreatic cancer are in Phase I or earlier. Despite growth in biologics, small molecules remain dominant in the pancreatic cancer pipeline


(Photo Courtesy:

While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52 percent of products categorized as first-in-class, most development is in the early stages, meaning a significant proportion of therapies are unlikely to reach the market in the near future, says business intelligence provider GBI Research.

The company's latest report states that while the pancreatic cancer treatment pipeline contains 447 therapeutics in active development across all Phases, compared to 209 currently-marketed products, almost 75 percent of therapies are in Phase I or earlier.

According to Mr Joshua Libberton, analyst, GBI Research, 58 percent of drugs in the pancreatic cancer treatment pipeline are in the discovery or preclinical stages, 17 percent are in Phase I and 21 percent are in Phase II, leaving just 4 percent of products in Phase III of development.

Mr Libberton comments: "While the Phase III portion of the pipeline is comparatively small, it is followed by a relatively large Phase II, indicating that there will be a sustained stream of products moving through the later development stages.

"Despite the majority of pancreatic cancer therapy development occurring in very early stages, many of the assessed targets showed promising preclinical results and a strong alignment to known disease-causing pathways, which could translate to clinical and commercial success."


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email